Skip to main content
Erschienen in: International Journal of Hematology 3/2013

01.03.2013 | Original Article

Clinical significance of jejunoileal involvement of non-Hodgkin’s lymphoma detected by double-balloon enteroscopy

verfasst von: Takashi Ibuka, Hisashi Tsurumi, Hiroshi Araki, Takeshi Hara, Fumito Onogi, Naoe Goto, Yasushi Kojima, Nobuhiro Kanemura, Makoto Shiraki, Senji Kasahara, Masahito Shimizu, Kengo Ogawa, Soranobu Ninomiya, Takayuki Nakanishi, Tomohiro Kato, Tsuyoshi Takami, Hisataka Moriwaki

Erschienen in: International Journal of Hematology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Jejunoileal involvement of non-Hodgkin’s lymphoma (NHL) is an important diagnostic factor in determining optimal treatment strategies. Here, we used double-balloon enteroscopy (DBE) to detect jejunoileal involvement of NHL and studied its clinical significance in a series of patients with NHL. Adults aged between 18 and 85 years with infiltration of the stomach, duodenum, or colon confirmed by gastrointestinal endoscopy or colonoscopy, suspected jejunoileal involvement determined by CT or FDG-PET, or any other gastrointestinal symptoms, were eligible for inclusion in the study. Among 428 patients with histologically confirmed NHL between 2004 and 2011, 83 were eligible for DBE, but 20 patients were excluded due to rejection or poor clinical status. Thus, 63 underwent DBE. The 3-year overall survival rate was significantly lower in patients with (n = 33), than without (n = 30) jejunoileal involvement of NHL confirmed by DBE (49 vs. 92 %, p < 0.005). Four participants developed aspiration pneumonia, but recovered after treatment with antibiotics.
Literatur
1.
Zurück zum Zitat Rosenberg SA, Diamond HD, Jaslowitz B, Craver LF. Lymphosarcoma: a review of 1269 cases. Medicine. 1961;40:31–84.PubMedCrossRef Rosenberg SA, Diamond HD, Jaslowitz B, Craver LF. Lymphosarcoma: a review of 1269 cases. Medicine. 1961;40:31–84.PubMedCrossRef
2.
Zurück zum Zitat Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–60.PubMedCrossRef Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–60.PubMedCrossRef
4.
Zurück zum Zitat Yamamoto H, Sekine Y, Sato Y, Higashizawa T, Miyata T, Iino S, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc. 2001;53:216–20.PubMedCrossRef Yamamoto H, Sekine Y, Sato Y, Higashizawa T, Miyata T, Iino S, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc. 2001;53:216–20.PubMedCrossRef
5.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001.
6.
Zurück zum Zitat May A, Nachbar L, Wardak A, Yamamoto H, Ell C. Double-balloon enteroscopy: preliminary experience in patients with obscure gastrointestinal bleeding or chronic abdominal pain. Endoscopy. 2003;35:985–91.PubMedCrossRef May A, Nachbar L, Wardak A, Yamamoto H, Ell C. Double-balloon enteroscopy: preliminary experience in patients with obscure gastrointestinal bleeding or chronic abdominal pain. Endoscopy. 2003;35:985–91.PubMedCrossRef
7.
Zurück zum Zitat Yamamoto H, Kita H, Sunada K, Hayashi Y, Sato H, Yano T, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. Clin Gastroenterol Hepatol. 2004;2:1010–6.PubMedCrossRef Yamamoto H, Kita H, Sunada K, Hayashi Y, Sato H, Yano T, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. Clin Gastroenterol Hepatol. 2004;2:1010–6.PubMedCrossRef
8.
9.
Zurück zum Zitat Takagi T, Oguro M. (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative: its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol. 1987;20:151–4.PubMedCrossRef Takagi T, Oguro M. (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative: its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol. 1987;20:151–4.PubMedCrossRef
10.
11.
Zurück zum Zitat Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol. 2004;130:107–13.PubMedCrossRef Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol. 2004;130:107–13.PubMedCrossRef
12.
Zurück zum Zitat Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107–14.PubMedCrossRef Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107–14.PubMedCrossRef
13.
Zurück zum Zitat Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, et al. Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol. 2010;136:65–70.PubMedCrossRef Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, et al. Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol. 2010;136:65–70.PubMedCrossRef
14.
Zurück zum Zitat Hara T, Tsurumi H, Kasahara S, Kanemura N, Yoshikawa T, Goto N, et al. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin’s lymphoma with higher cost-effectiveness. Int J Hematol. 2005;82:430–6.PubMedCrossRef Hara T, Tsurumi H, Kasahara S, Kanemura N, Yoshikawa T, Goto N, et al. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin’s lymphoma with higher cost-effectiveness. Int J Hematol. 2005;82:430–6.PubMedCrossRef
15.
Zurück zum Zitat Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol. 2002;68:354–61.PubMedCrossRef Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol. 2002;68:354–61.PubMedCrossRef
16.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
17.
Zurück zum Zitat Yoshino T, Miyake K, Ichimura K, Mannami T, Ohara N, Hamazaki S, et al. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol. 2000;24:688–93.PubMedCrossRef Yoshino T, Miyake K, Ichimura K, Mannami T, Ohara N, Hamazaki S, et al. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol. 2000;24:688–93.PubMedCrossRef
18.
Zurück zum Zitat Shia J, Teruya-Feldstein J, Pan D, Hegde A, Klimstra DS, Chaganti RS, et al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol. 2002;26:216–24.PubMedCrossRef Shia J, Teruya-Feldstein J, Pan D, Hegde A, Klimstra DS, Chaganti RS, et al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol. 2002;26:216–24.PubMedCrossRef
19.
Zurück zum Zitat Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol. 2003;14:623–9.PubMedCrossRef Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol. 2003;14:623–9.PubMedCrossRef
20.
Zurück zum Zitat Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–73.PubMedCrossRef Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–73.PubMedCrossRef
21.
Zurück zum Zitat Smith GA, O’Dwyer PJ. Sensitivity of double contrast barium enema and colonoscopy for the detection of colorectal neoplasms. Surg Endosc. 2001;15:649–52.PubMedCrossRef Smith GA, O’Dwyer PJ. Sensitivity of double contrast barium enema and colonoscopy for the detection of colorectal neoplasms. Surg Endosc. 2001;15:649–52.PubMedCrossRef
22.
Zurück zum Zitat Postic G, Lewin D, Bickerstaff C, Wallace MB. Colonoscopic miss rates determined by direct comparison of colonoscopy with colon resection specimens. Am J Gastroenterol. 2002;97:3182–5.PubMedCrossRef Postic G, Lewin D, Bickerstaff C, Wallace MB. Colonoscopic miss rates determined by direct comparison of colonoscopy with colon resection specimens. Am J Gastroenterol. 2002;97:3182–5.PubMedCrossRef
23.
Zurück zum Zitat Matsumoto T, Esaki M, Moriyama T, Nakamura S, Iida M. Comparison of capsule endoscopy and enteroscopy with the double-balloon method in patients with obscure bleeding and polyposis. Endoscopy. 2005;37:827–32.PubMedCrossRef Matsumoto T, Esaki M, Moriyama T, Nakamura S, Iida M. Comparison of capsule endoscopy and enteroscopy with the double-balloon method in patients with obscure bleeding and polyposis. Endoscopy. 2005;37:827–32.PubMedCrossRef
24.
Zurück zum Zitat Kameda N, Higuchi K, Shiba M, Machida H, Okazaki H, Yamagami H, et al. A prospective, single-blind trial comparing wireless capsule endoscopy and double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. J Gastroenterol. 2008;43:434–40.PubMedCrossRef Kameda N, Higuchi K, Shiba M, Machida H, Okazaki H, Yamagami H, et al. A prospective, single-blind trial comparing wireless capsule endoscopy and double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. J Gastroenterol. 2008;43:434–40.PubMedCrossRef
25.
Zurück zum Zitat Mönkemüller K, Weigt J, Treiber G, Kolfenbach S, Kahl S, Röcken C. Diagnostic and therapeutic impact of double-balloon enteroscopy. Endoscopy. 2006;38:67–72.PubMedCrossRef Mönkemüller K, Weigt J, Treiber G, Kolfenbach S, Kahl S, Röcken C. Diagnostic and therapeutic impact of double-balloon enteroscopy. Endoscopy. 2006;38:67–72.PubMedCrossRef
26.
Zurück zum Zitat May A, Nachbar L, Pohl J, et al. Endoscopic interventions in the small bowel using double balloon enteroscopy: feasibility and limitations. Am J Gastroenterol. 2007;102:527–35.PubMedCrossRef May A, Nachbar L, Pohl J, et al. Endoscopic interventions in the small bowel using double balloon enteroscopy: feasibility and limitations. Am J Gastroenterol. 2007;102:527–35.PubMedCrossRef
27.
Zurück zum Zitat A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.
28.
Zurück zum Zitat Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.PubMedCrossRef Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.PubMedCrossRef
29.
Zurück zum Zitat Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRef Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRef
30.
Zurück zum Zitat Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.PubMedCrossRef Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.PubMedCrossRef
31.
Zurück zum Zitat Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, et al. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol. 2000;64:257–61.PubMedCrossRef Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, et al. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol. 2000;64:257–61.PubMedCrossRef
32.
Zurück zum Zitat Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, et al. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. J Cancer Res Clin Oncol. 2009;135:1421–8.PubMedCrossRef Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, et al. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. J Cancer Res Clin Oncol. 2009;135:1421–8.PubMedCrossRef
33.
Zurück zum Zitat Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol. 2005;131:73–9.PubMedCrossRef Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol. 2005;131:73–9.PubMedCrossRef
34.
Zurück zum Zitat Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol. 2006;77:217–25.PubMedCrossRef Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol. 2006;77:217–25.PubMedCrossRef
35.
Zurück zum Zitat Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol. 2009;135:53–9.PubMedCrossRef Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol. 2009;135:53–9.PubMedCrossRef
36.
Zurück zum Zitat Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, et al. Serum concentration of l-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol. 2010;84:304–9.PubMedCrossRef Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, et al. Serum concentration of l-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol. 2010;84:304–9.PubMedCrossRef
37.
Zurück zum Zitat Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol. 1992;141:1361–71.PubMed Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol. 1992;141:1361–71.PubMed
38.
Zurück zum Zitat Katoh A, Ohshima K, Kanda M, Haraoka S, Sugihara M, Suzumiya J, et al. Gastrointestinal T cell lymphoma: predominant cytotoxic phenotypes, including alpha/beta, gamma/delta T cell and natural killer cells. Leuk Lymphoma. 2000;39:97–111.PubMedCrossRef Katoh A, Ohshima K, Kanda M, Haraoka S, Sugihara M, Suzumiya J, et al. Gastrointestinal T cell lymphoma: predominant cytotoxic phenotypes, including alpha/beta, gamma/delta T cell and natural killer cells. Leuk Lymphoma. 2000;39:97–111.PubMedCrossRef
Metadaten
Titel
Clinical significance of jejunoileal involvement of non-Hodgkin’s lymphoma detected by double-balloon enteroscopy
verfasst von
Takashi Ibuka
Hisashi Tsurumi
Hiroshi Araki
Takeshi Hara
Fumito Onogi
Naoe Goto
Yasushi Kojima
Nobuhiro Kanemura
Makoto Shiraki
Senji Kasahara
Masahito Shimizu
Kengo Ogawa
Soranobu Ninomiya
Takayuki Nakanishi
Tomohiro Kato
Tsuyoshi Takami
Hisataka Moriwaki
Publikationsdatum
01.03.2013
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2013
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1273-4

Weitere Artikel der Ausgabe 3/2013

International Journal of Hematology 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.